Long-Term Metabolic Consequences of Switching from Protease Inhibitors to Efavirenz in Therapy for Human Immunodeficiency Virus—Infected Patients with Lipoatrophy.
Saved in:
| Title: | Long-Term Metabolic Consequences of Switching from Protease Inhibitors to Efavirenz in Therapy for Human Immunodeficiency Virus—Infected Patients with Lipoatrophy. |
|---|---|
| Authors: | Estrada, V., de Villar, N. G. P., Martinez Larrad, M. L., Gonzalez Lopez, A., Fernandez, C., Serrano-Rios, M. |
| Source: | Clinical Infectious Diseases. 7/1/2002, Vol. 35 Issue 1, p69-76. 8p. |
| Database: | Environment Complete |
| ISSN: | 10584838 |
|---|---|
| DOI: | 10.1086/340863 |
